For discussion of the mutual effects of pregnancy and inflammatory bowel disease (IBD) upon each other, the following classification proposed by Abramson' will be used: Group 1 -IBD inactive at conception; Group 2 -IBD active at conception; Group 3 -IBD arising during gestation; Group 4 -IBD arising during the puerperium. However, the number of cases in Groups 3 and 4 is so small, even in the larger series, that few generalizations can be made.
Fertility
It is frequently stated that fertility is normal in ulcerative colitis (UC) but impaired in Crohn's disease (CD) . The data are, however, inadequate to be certain of this. Early series2`4 report a third to a half of their patients with UC of childbearing potential becoming pregnant. Some authors have reported pregnancy rates lower in UC than in the general population5, but in one recent series6 only 7% of UC patients were involuntarily infertile. Impaired fertility has been said to be more likely in Crohn's colitis than in small bowel disease7. This has not been the general experience, but pregnancy rates have been found to be lower in CD than the general population8'9. However, the Oxford group recently reported that only 11% of their Crohn's patients were involuntarily infertile'0. Factors suggested as underlying subfertility include tubal occlusion, nutritional deficiencies and the presence of active disease. Indeed, patients who have undergone resections have been said to have higher pregnancy rates8.
It has to be remembered that the literature values for infertility in IBD are overestimates, since longer follow up can only increase the number of pregnancies, and in most series it was not certain that all the eligible patients were trying to conceive. Table 1 summarizes the outcome of 1308 pregnancies in women with UC reported in ten major series' -4 -. The overall figures are similar to the general population and the average UC patient has a very good chance of a normal full-term delivery. Group 2 patients (disease active at conception) may be more likely to have a spontaneous abortion or premature delivery than Group 16,15. It has also been postulated that UC patients have a higher chance of producing a low birth-weight baby at term5, but this is not the general experience. In some series the chance of a normal child is higher than apparent from Table 1 . Induced abortions for general reasons are permitted in Denmark before the twelfth week. There were 19 such cases in the report by Nielsen et al.'5 for which there was no medical reason. If these cases are omitted, the proportion of normal babies could rise from 76% to 85% in that series.
Effect of IBD on pregnancy
The results of 748 pregnancies in CD reported in nine major series7'-10,14,16 -19 are shown in Table 2 .
Again the overall chances of a normal baby are similar to those in the general population. However, the coexistence of severe disease (Group 2) may lead to an increase in the risk of spontaneous abortion, stillbirth or premature delivery'0"79. Once again there is a high rate of terminations for personal reasons in the Danish series'9. Without these cases the chance of a normal baby may rise to 83.5% in that report.
Based on paper read to Sections of Obstetrics & Gynaecology and Colo-Proctology, 29 March 1985 Effect of pregnancy on ulcerative colitis Table 3 shows the likelihood of relapse in patients with inactive disease at conception in eight of the series -already quoted' -4,6,11,12,15 . About a third of cases will relapse during the twelve months of gestation and the puerperium. This is similar to the relapse rate for a group of non-pregnant colitics followed for a year4",5. Thus there is no good evidence for an effect of pregnancy on UC in Group 1 cases. The first trimester seems to be a period of high risk for relapse46"5. The second trimester'5 and puerperium4 have also been reported as times of high risk, but this is not generally agreed.
In patients with active disease at the time of conception, roughly 45% will get worse while about a quarter will improve and a quarter will remain unchanged ( Table 4 ). Thus virtually three out of four patients will have active disease during the course of their pregnancy. We have already seen that the chances of a normal baby may be reduced in these patients.
There are no large series of patients in Groups 3 and 4. Some of the older reports suggest that these cases can be particularly severe with a high risk to the mother' -3.1 However, the modern experience with steroids and sulphasalazine contradicts this6" 5.
Although there are few data, it is reported that one cannot predict the course of UC in subsequent pregnancies in the same woman on the basis of previous pregnancies2.
Effect of pregnancy on Crohn's disease About a quarter of Group 1 patients with CD had a relapse during pregnancy or the puerperium (Table  5 ), though the rates vary considerably between different series and could be as high as 40%. However, it may be that these rates do not differ from those for the non-pregnant patient with CD followed for a similar period'8"9. Again the first trimester or the puerperium are suggested as the most likely times for relapse7'8"0.
In Group 2 patients with CD it appears that approximately a third will improve, a third will remain unchanged and a third will deteriorate during the course of gestation and the puerperium ( Table 6 ). Thus two-thirds of such patients are likely to have to contend with active disease during pregnancy. Not all authors have used the classification of Abramson' and their data cannot therefore be included in the above analysis. Others agree that in general the activity of CD is likely to be little changed during the course of gestation7 8"7. It may be that those patients who have previously had resections are less likely to suffer relapse8 6.
Few Group 3 and 4 cases have been reported but it has been claimed that the outlook for the fetus can be poor in Group 3 cases20. Drug treatment ofIBD during pregnancy Many of the large series already quoted have used sulphasalazine and steroids and the relatively normal outcome for the majority of pregnancies is broadly reassuring. Several authors have discussed drug treatment in detail5,6"10"14"15,19,21 -23 There have been reports6"14"19'23 of a higher incidence of fetal complications when the mother has received drug treatment during pregnancy, but the authors' analysis has usually been that this is more likely to have been related to disease activity than the drugs per se. The consensus is that these drugs should be used for IBD during pregnancy much as they are in the non-pregnant. Less information is available for azathioprine and the issue is contentious.
Sulphasalazine
Sulphasalazine24 comprises 5-amino-salicylic acid (5ASA) linked to sulphapyridine (SP) by an azo bond. About 30% of an oral dose is absorbed in the small intestine, the rest passing to the distal small bowel and colon where bacteria split the drug into its constituent 5ASA and SP. The SP is absorbed from the colon and excretedin the urine either unchanged or as conjugates. The 5ASA is largely unabsorbed and it now appears that this is the therapeutic moiety, while the SP can be regarded as a vehicle which carries the 5ASA to its site of action in the colon and distal small bowel24. Interestingly many of the unwanted effects of sulphasalazine appear to be due to the SP, and much effort is being expended in the development of preparations without SP whidh will deliver 5ASA to the distal bowel. The first of these (Mesalazine or Asacol, Tillotts Laboratories) has just been marketed and incorporates the 5ASA into an acrylic resin which releases its contents when the luminal pH reaches 7 or above. It should prove useful for sulphasalazine-intolerant subjects25'26.
Sulphonamides have the potential to promote kernicterus by displacing bilirubin from albumin.
Sulphasalazine and sulphapyridine do cross the placenta and the concentrations are similar in cord and maternal serum, though concentrations of 5ASA are very low because of its poor absorption27'28.
Nevertheless, kernicterus has not been a problem in the series quoted here, because the displacement of bilirubin is negligible at the concentrations of sulphasalazine and sulphapyridine found in cord blood28 '29. No firm evidence of any harmful effect of sulphasalazine for the fetus has emerged and the consensus of the literature already quoted is that it should be used for the treatment of IBD in pregnancy much as it is in the non-pregnant.
Concentrations of sulphasalazine. and its metabolites are lower in milk than in maternal and cord serum and are thought unlikely to be harmful27 '30 Sulphasalazine causes reversible infertility in the male31, and thus in the investigation of infertility IBD in the husband may be very relevant. This is probably due to the sulphapyridine component and seems unlikely to be a problem with the newer 5ASA preparations32'33.
Corticosteroids
Corticosteroids cross the placenta, but it seems that cortisol is rapidly converted to the more inactive cortisone34 and prednisone and prednisolone levels in the fetal circulation are only 10-12% of those in the maternal circulation35. This presumably explains the rarity of fetal hypothalamic-pituitaryadrenal suppression when steroids are given to the mother during gestation36'37.
Much of the published data on the outcome of pregnancies where the mother has received corticosteroids concerns conditions other than IBD, such as asthma, systemic lupus erythematosus and rheumatoid disease. Some reports suggest an increase in stillbirths38 or a reduction ip birthweight39. The absence of follow-up data makes it unclear whether there were any long-term implications of low birthweight for the fetus in the latter report. Nevertheless, the majority of reports40 are reassuring, as are those studies on IBD where the results have been specifically analysed in relation to the drug treatment the mother had received6'10'14 S 19. In some instances, however, the number of cases studied is small. Where congenital anomalies have occurred they have often been relatively minor (cleft palate, hare lip, finger anomaly, congenital dislocation of the hip) with no evidence that they were more frequent than in pregnancies where the mother had not received drugs.
It appears that little prednisolone (e.g. 0.07-0.23% of a single test dose) enters the milk47 and it may be that breastfeeding is safe; however more data are required before complete reassurance can be given. 35 47 Urinary oestriol excretion may be reduced in pregnancy in women receiving steroids without evidence of fetal distress or intrauterine growth retardation48.
Azathioprine
It has been said that azathioprine exposure is sufficient reason for termination22 and that it should not be used in pregnancy2' because of the high incidence of fetal abnormalities in animals and the recorded abnormalities in man which have included thymic hypoplasia, lymphopenia, reduced serum immunoglobulin concentrations and chromatid breaks49 50. However these abnormalities tended to improve in the early months of life and, while more follow-up information is required, it is far from certain that the children suffered long-term consequences.
By contrast, normal deliveries of mothers taking steroids and azathioprine have been reported mainly in the renal transplantation literature5-54. Data from 109 successful pregnancies in transplanted women were published in 198053 and information from a further 166 pregnancies is to be published54. Data on incomplete pregnancies (therapeutic and spontaneous abortions) are not presented. A high proportion of the mothers were taking a combination of steroids and azathioprine. Pre-term and Caesarian deliveries were common. Three-quarters of the babies had birthweights in excess of 2.5kg. The precise incidence of stillbirth and congenital abnormality is uncertain because of the incorporation of some data from untransplanted mothers on dialysis. Nevertheless, the incidence of congenital abnormality did not exceed 4% of the babies born to transplanted mothers.
Azathioprine is probably best avoided where possible in the pregnant woman with IBD. In exceptional cases, and where conception has occurred while on the drug, it seems reasonable to proceed with a wanted pregnancy after detailed discussion with the parents of the uncertainties involved.
Conclusions
There is little evidence that pregnancy exerts a consistent effect on the course of IBD, and overall the chances that the baby will be normal approach those for the general population. However, patients should be advised to conceive when in remission if possible, since those with active disease at conception may have an increased chance of abortion or stillbirth. Sulphasalazine and steroids should probably be used as in the non-pregnant, in the minimum dosage compatible with maternal health. Certainly, IBD is not a reason for a young woman to avoid pregnancy or undergo therapeutic abortion in any but the most exceptional case. Other reviews of the subject have been published by Vender and Spiro2', Sorokin and Levine22, Miller55 and Donaldson56.
